PYC Therapeutics Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Rohan Hockings

Chief executive officer

AU$433.2k

Total compensation

CEO salary percentage	91.2%
CEO tenure	4.1yrs
CEO ownership	n/a
Management average tenure	4.1yrs
Board average tenure	5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rohan Hockings's remuneration changed compared to PYC Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$433k	AU$395k	-AU$38m
Mar 31 2024	n/a	n/a	-AU$30m
Dec 31 2023	n/a	n/a	-AU$22m
Sep 30 2023	n/a	n/a	-AU$22m
Jun 30 2023	AU$438k	AU$395k	-AU$23m
Mar 31 2023	n/a	n/a	-AU$23m
Dec 31 2022	n/a	n/a	-AU$24m
Sep 30 2022	n/a	n/a	-AU$19m
Jun 30 2022	AU$418k	AU$395k	-AU$14m
Mar 31 2022	n/a	n/a	-AU$15m
Dec 31 2021	n/a	n/a	-AU$17m
Sep 30 2021	n/a	n/a	-AU$17m
Jun 30 2021	n/a	n/a	-AU$18m
Mar 31 2021	n/a	n/a	-AU$15m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$9m
Jun 30 2020	AU$471k	AU$395k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$5m
Sep 30 2019	n/a	n/a	-AU$5m
Jun 30 2019	AU$482k	AU$395k	-AU$4m
Mar 31 2019	n/a	n/a	-AU$4m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$6m
Jun 30 2018	AU$377k	AU$84k	-AU$7m

Compensation vs Market: Rohan's total compensation ($USD298.31K) is below average for companies of similar size in the Australian market ($USD896.97K).

Compensation vs Earnings: Rohan's compensation has been consistent with company performance over the past year.

CEO

Rohan Hockings (41 yo)

4.1yrs

Tenure

AU$433,210

Compensation

Dr. Rohan Hockings, MBBS (Hons.), J.D., G.D.L.P, has been Chief Executive Officer at PYC Therapeutics Limited since August 2020. He served as Chief Strategy Officer at PYC Therapeutics Limited until August...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rohan Hockings	CEO & Executive Director	4.1yrs	AU$433.21k	no data
Andrew Taylor	CFO & Company Secretary	2.4yrs	no data	no data
Kevin Hart	Company Secretary	7.2yrs	AU$165.90k	no data

4.1yrs

Average Tenure

Experienced Management: PYC's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Rohan Hockings	CEO & Executive Director	5.8yrs	AU$433.21k	no data
Michael Rosenblatt	Independent Non-Executive Director	3.5yrs	AU$86.67k	no data
Stephen Doberstein	Member of Scientific Advisory Board	6.9yrs	no data	no data
David Birch	Member of Ophthalmology Clinical Advisory Board	3.1yrs	no data	no data
Judy Lieberman	Member of Scientific Advisory Board	6.9yrs	no data	no data
Shohei Koide	Member of Scientific Advisory Board	5.8yrs	no data	no data
Jason Haddock	Independent Director	3.5yrs	AU$86.67k	no data
Alan Tribe	Non-Executive Chair of the Board	6.4yrs	AU$70.00k	34.02% A$ 285.7m
Rakesh Veedu	Member of Scientific Advisory Board	5.5yrs	no data	no data
Fred Chen	Member of Scientific Advisory Board & Member of Ophthalmology Clinical Advisory Board	5yrs	no data	no data
Mark Pennesi	Member of Ophthalmology Clinical Advisory Board	3.1yrs	no data	no data
Jacque Duncan	Member of Ophthalmology Clinical Advisory Board	3.1yrs	no data	no data

5.3yrs

Average Tenure

65yo

Average Age

Experienced Board: PYC's board of directors are considered experienced (5.3 years average tenure).

PYC Therapeutics Management

Management criteria checks 4/4

Key information

Recent management updates

Insufficient new directors

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

High number of new and inexperienced directors

Recent updates

Insufficient new directors

PYC Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 74.657302 million.

Forecast to breakeven in 2026

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board recently bought AU$81k worth of stock

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy